Pharmaceutical company in the
Canton of Vaud

Sincopharm S.A.

Since 1989 · 11–20 empl.

Sincopharm S.A. develops and manufactures cosmetic products and formulations for clients. Its services include research and development, production, physico-chemical quality control, regulatory support, and filling and packaging.

Haleon CH SARL

Since 1991 · 21–50 empl.

Haleon CH SARL operates in consumer health, with a focus on products for everyday health. The Haleon group’s portfolio includes oral care, vitamins and supplements, pain relief, and products for respiratory, digestive and skin health.

Matrixsanos Sàrl

Since 1996 · 1–10 empl.

Matrixsanos Sàrl manufactures chromopuncture instruments, ultrasonic devices to deter martens, and instruments for producing silver and copper colloids. The company supplies specialized products for therapists and for personal use.

Pharmacie des hôpitaux du Nord vaudois et de la Broye (PHNVB)

Since 1998 · 21–50 empl.

Pharmacie des hôpitaux du Nord vaudois et de la Broye (PHNVB) is a non-profit hospital pharmacy and a legally independent association. It procures and distributes medicines and other products to its member institutions, prepares sterile and non-sterile products, and provides pharmaceutical support and clinical pharmacy services.

Ferring International Center SA

Since 2000 · 21–50 empl.

Ferring International Center SA is part of the biopharmaceutical Ferring group, which develops medicines and works in reproductive medicine, maternal and child health, gastroenterology and urology. The site is listed for manufacturing and research and development.

Dompé International SA

Since 2002 · 1–10 empl.

Dompé International SA is a biopharmaceutical company engaged in research, development and manufacturing of medicines. It focuses on ophthalmic, neurological and pain‑related indications, including development of recombinant human nerve growth factor (rhNGF), and employs virtual screening technologies such as the Exscalate platform for drug discovery.

FONDATION EUROVACC

Since 2002 · 11–20 empl.

FONDATION EUROVACC is a non-profit foundation that promotes research and development of vaccines against HIV and other infectious diseases. It supports the translation of research into early-phase clinical trials and collaborates with academic groups and other partners.

Haut-Lac Ecole Internationale Bilingue SA

Since 2003 · 11–20 empl.

Thermo Fisher Scientific is a leading company in the life science industry, specializing in the development, manufacture and distribution of products and services for research, development and production of pharmaceuticals, biotechnology and environmental analysis. The company's core activities include research and development, manufacturing of laboratory equipment and supplies, diagnostics, pharmaceutical development and production, as well as environmental analysis.

Merck Performance Materials (Suisse) SA

Since 2003 · 101–500 empl.

Merck Performance Materials (Suisse) SA is part of the Merck Group and operates in Switzerland across the Healthcare, Life Science and Electronics businesses. The company develops and supplies products, technologies and services for research, medical applications, and electronics and semiconductor uses.

Copexis SA

Since 2004 · 11–20 empl.

Copexis SA is a consultancy specialising in drug development and regulatory services in Switzerland and the EU. It advises and provides hands-on support for manufacturing, toxicology and clinical programmes, as well as corporate development and management.

EFFIK SA

Since 2006 · 11–20 empl.

EFFIK SA is a pharmaceutical company offering products in gynaecology, neurology, haematology and cardiology. Its portfolio includes medicines and food supplements for contraception, pregnancy and breastfeeding, vaginal health and other therapeutic uses.

Ferring Pharmaceuticals SA

Since 2007 · 101–500 empl.

Ferring Pharmaceuticals SA is a biopharmaceutical company that develops medicines and therapies for gastroenterology, urology and reproductive medicine. The company conducts research, clinical development and maintains a product pipeline.

AMAZENTIS SA

Since 2007 · 11–20 empl.

AMAZENTIS SA is a life-sciences biotechnology company that researches Urolithin A and develops the ingredient Mitopure®. It studies applications in cellular health and develops related nutrition and skincare products, offered through its Timeline brand.

PRECLIN Biosystems SA

Since 2008 · 1–10 empl.

PRECLIN Biosystems SA provides preclinical in vivo testing to identify and validate therapeutic candidates. It offers models for chronic inflammatory and infectious diseases and studies efficacy, mechanisms of action and potential side effects.

NovaPharm SA

Since 2008 · 1–10 empl.

NovaPharm SA is a healthcare-sector company providing consulting, operational services and trading. It advises pharmaceutical companies and pharmacies, supports activities such as logistics, sourcing and regulatory compliance, and wholesales, imports and exports medicines and other healthcare products.

Excellness Biotech SA

Since 2009 · 1–10 empl.

Excellness Biotech SA develops and sells biomedical cell culture products, including elastic substrates that mimic the mechanical properties of human tissues. Its products support cell culture applications and the study and measurement of contraction in cells and tissue samples.

HRA-Pharma Switzerland Sàrl

Since 2009 · 1–10 empl.

HRA-Pharma Switzerland Sàrl is a company active in self-care and consumer health products. The website presents products and solutions for conditions that can be self-managed or prevented, including areas such as cold and respiratory care, pain relief, skincare, oral care and women's health.

Asceneuron SA

Since 2012 · 11–20 empl.

Asceneuron SA develops orally administered therapies for neurodegenerative diseases. It researches small-molecule drugs intended to inhibit abnormal protein aggregation in the brain, including in Alzheimer’s disease, Parkinson’s disease and tauopathies.

Laboratoire Pharmessence, Luc-Henri Geny

Since 2013 · 1–10 empl.

Laboratoire Pharmessence, Luc-Henri Geny manufactures and distributes medicines and plant-based products for medical use. Its range includes essential and vegetable oils, hydrolats, plant extracts, and compounded preparations for healthcare professionals.

fondation Innovative Medicines for Tuberculosis (iM4TB)

Since 2014 · 11–20 empl.

fondation Innovative Medicines for Tuberculosis (iM4TB) supports research and development of medicines to treat tuberculosis. It backs the preclinical and clinical development of drug candidates and works to bridge the gap between scientific discovery and bringing treatments to market.

Floratek Pharma SA

Since 2015 · 11–20 empl.

Floratek Pharma SA is a pharmaceutical company developing novel therapeutics, primarily for the treatment of cancer. It researches plant-derived compounds and uses artificial intelligence and computational modelling for drug discovery and optimisation.

Combioxin SA

Since 2015 · 11–20 empl.

Combioxin SA is a clinical-stage biotechnology company developing medicines for severe infections and acquired immune deficiency in critically ill patients. Its pipeline includes CAL02, a liposomal drug candidate designed to neutralize bacterial toxins in severe community-acquired bacterial pneumonia.

Hartis-Pharma SA

Since 2016 · 11–20 empl.

Hartis-Pharma SA is a biotechnology company researching and developing treatments for conditions that may benefit from the functions of high-density lipoproteins (HDL). Its work focuses on regulating cell-membrane cholesterol and transporting liposoluble antioxidants, particularly in relation to sickle cell disease and thalassemia.

Axalbion SA

Since 2017 · 11–20 empl.

Axalbion SA is a biopharmaceutical company developing AX-8, a locally delivered TRPM8 agonist for refractory chronic cough. The program is advancing toward Phase 2b development.

Fresenius Kabi SwissBioSim GmbH

Since 2017 · 1–10 empl.

Fresenius Kabi SwissBioSim GmbH is an affiliated company of Fresenius Kabi in the biopharmaceutical sector. Fresenius Kabi’s Biopharma business develops, manufactures and supplies biosimilars, biological medicines highly similar to approved reference medicines.

Swiss Medical Cannabis SA

Since 2017 · 11–20 empl.

Swiss Medical Cannabis SA sells hemp and cannabis products through an online shop and supplies these products via pharmacies and other retail partners.

Tigen Pharma SA

Since 2017 · 11–20 empl.

Tigen Pharma SA is a biotechnology company developing cell therapies for cancer. Its focus includes autologous T-cell therapies, such as CAR-T and TIL approaches, and the development of a manufacturing platform for cell and gene therapies.

iGreen Swiss SA

Since 2017 · 1–10 empl.

iGreen Swiss SA produces and develops medical cannabis products and cannabinoids such as THC and CBD. Its activities include cultivating medicinal plants and offering products such as dried flowers and extracts for therapeutic use, research and the pharmaceutical industry.

Pharmotech SA

Since 2018 · 1–10 empl.

Pharmotech SA is a research and development company in phytopharmaceuticals. It investigates applications of cannabidiol against antibiotic-resistant bacteria and develops and markets PSEUDOMA®, a CBD-containing hand disinfectant.

LAM Biotechnologies SA

Since 2018 · 1–10 empl.

LAM Biotechnologies SA is a biotechnology company focused on research and development, production of its own products, and sales and marketing of those products. It also provides services in diagnostics, platform technologies, analytical testing, screening, and bioinformatics.

Bial SA

Since 2018 · 21–50 empl.

The core activity of BIAL is the development, manufacture and marketing of medicines and therapeutic solutions in the healthcare sector. The company focuses particularly on research and development of new medicines and therapies to improve the quality of life of people worldwide.

Haya Therapeutics SA

Since 2019 · 21–50 empl.

Haya Therapeutics SA is a biotechnology company developing RNA-based therapeutics. Its regulatory-genome platform identifies disease-related non-coding RNAs and supports the development of antisense therapies, including for fibrotic, metabolic and age-related diseases.

Green Gold Health SA

Since 2019 · 1–10 empl.

Green Gold Health SA trades in health and wellbeing products, including CBD cosmetics and oils and dietary supplements. Its activities also cover pharmaceutical products, in-vitro diagnostics and sourcing healthcare products.

Onward Therapeutics SA

Since 2019 · 1–10 empl.

Onward Therapeutics SA is a clinical-stage biotechnology company developing treatments for cancer. Its pipeline includes a bispecific antibody, an allogeneic natural killer cell therapy and a small-molecule drug candidate.

Orgenesis Switzerland Sàrl

Since 2020 · 11–20 empl.

Orgenesis Switzerland Sàrl develops and implements the POCare platform for cell and gene therapies, focusing on process development, validation and automated closed‑loop bioprocessing units (OMPUL™) for decentralized point‑of‑care production.

Horus Pharma Suisse SA

Since 2021 · 101–500 empl.

The core activity of Horus Pharma is the development, manufacture and marketing of pharmaceuticals, medical devices and dietary supplements, particularly in the fields of ophthalmology, dermatology and surgery. The company focuses on creating therapeutic solutions and accompanying services for doctors and patients, with an emphasis on innovation, ethics and patient benefit.

Vandria SA

Since 2021 · 21–50 empl.

Vandria SA is a clinical-stage biotechnology company developing small-molecule drug candidates for age-related and chronic diseases. Its candidates are designed to restore mitochondrial function and reduce inflammation; its lead clinical candidate, VNA-318, has completed a Phase I study.

Oculis Operations Sàrl

Since 2022 · 21–50 empl.

The core activity of Oculis is the development and research of innovative treatments and medications for eye diseases, particularly in the areas of Diabetic Maculopathy, dry eye, Uveitis and acute Optic Neuritis. The company focuses on developing highly effective and patient-centered solutions to improve the treatment of eye diseases and preserve patients' vision.